Kura Oncology, Inc. (KURA): Price and Financial Metrics


Kura Oncology, Inc. (KURA): $18.17

0.96 (+5.58%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add KURA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

KURA Stock Price Chart Interactive Chart >

Price chart for KURA

KURA Price/Volume Stats

Current price $18.17 52-week high $23.00
Prev. close $17.21 52-week low $10.41
Day low $16.81 Volume 1,491,800
Day high $18.35 Avg. volume 760,465
50-day MA $13.80 Dividend yield N/A
200-day MA $15.37 Market Cap 1.21B

Kura Oncology, Inc. (KURA) Company Bio


Kura Oncology is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of solid tumors and blood cancers. The company was founded in 2014 and is based in La Jolla, California.


KURA Latest News Stream


Event/Time News Detail
Loading, please wait...

KURA Latest Social Stream


Loading social stream, please wait...

View Full KURA Social Stream

Latest KURA News From Around the Web

Below are the latest news stories about Kura Oncology Inc that investors may wish to consider to help them evaluate KURA as an investment opportunity.

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q4 2021 Results - Earnings Call Transcript

Kura Oncology, Inc. (KURA) Q4 2021 Earnings Conference Call February 24, 2022, 4:30 PM ET Company Participants Troy Wilson – Chairman, Chief Executive Officer & President Tom Doyle – Senior Vice President of Finance and Accounting Pete De Spain – Vice President, Investor Relations & Corporate Communications Conference Call Participants...

SA Transcripts on Seeking Alpha | February 25, 2022

Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results

– Patient enrollment continues in KOMET-001 Phase 1b study of ziftomenib (KO-539) in AML – – Multiple milestones and data readouts from KOMET-001 expected in 2022 – – First patients dosed in Phase 1/2 study of tipifarnib plus alpelisib in HNSCC – – Abstract supporting next-generation FTI program accepted for presentation at AACR – – $518 million in cash, cash equivalents and investments provide runway into 2024 – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO,

Yahoo | February 24, 2022

Kura Oncology to Report Fourth Quarter and Full Year 2021 Financial Results

SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2021 financial results after the close of U.S. financial markets on Thursday, February 24, 2022. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial resu

Yahoo | February 17, 2022

Kura Oncology to Participate in SVB Leerink Global Healthcare Conference

SAN DIEGO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 12:40 p.m. PT / 3:40 p.m. ET on Thursday, February 17, 2022. A live aud

Yahoo | February 10, 2022

We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | February 7, 2022

Read More 'KURA' Stories Here

KURA Price Returns

1-mo 34.49%
3-mo 12.58%
6-mo 20.65%
1-year -18.30%
3-year -8.19%
5-year 111.28%
YTD 29.79%
2021 -57.13%
2020 137.53%
2019 -2.07%
2018 -8.24%
2017 159.32%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5962 seconds.